TASTY taste-steering for chemotherapy-related taste changes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, non-blinded randomized trial uses a parallel cluster design by hospital across 12 centers in the Netherlands to compare at-home taste steering versus usual care. Hospitals are randomized as clusters to avoid cross-contamination between patients in different arms. Participants complete online questionnaires and undergo taste and smell tests plus saliva collection at baseline, at onset of taste or smell alterations (week 0), and after six weeks, while the intervention group receives tailored at-home taste-steering guidance and the control group receives standard care. The trial enrolls adults starting chemotherapy for specified cancers who can eat solids and meet nutrition and mucositis criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 and ≤70 years
* Indication to start chemotherapy for:

  * Metastatic triple negative breast cancer
  * Metastatic testicular cancer
  * Stage II-IV diffuse large B cell lymphoma
* Chemotherapy scheduled to start in the next 6 weeks
* Consuming solid foods and drinks is possible
* ≤50% of recommended daily intake in kcal consists of oral nutritional supplements
* Oral mucositis grade ≤2 (Common Terminology Criteria for Adverse Events, version 5.0)
* Ability to comply with all protocol-required actions
* Written informed consent
* For the intervention phase only: subjective change in taste since start of chemotherapy

Exclusion Criteria:

* Pregnancy
* Currently experiencing taste or smell problems
* Previous or current radiotherapy of head and neck region
* Enteral feeding through tube or parenteral feeding
* Participation in another clinical trial aimed at preventing or treating taste and/or smell alterations
* Chronic (\>1 month) high dose corticosteroids (\>10 mg prednisone/day or equivalent).

Where it's running

• Amsterdam UMC
  Amsterdam, Netherlands Recruiting
• Ziekenhuisvoorzieningen Gelderse Vallei
  Ede, Netherlands Recruiting
• University Medical Center Groningen
  Groningen, Netherlands Recruiting
• Martini Ziekenhuis
  Groningen, Netherlands Recruiting
• Ikazia Ziekenhuis
  Rotterdam, Netherlands Recruiting
• Ommelander Ziekenhuis Groningen
  Scheemda, Netherlands Recruiting

Study contacts

• Principal investigator: J. J. de Haan, MD, PhD — University Medical Center Groningen, Dept. of Medical Oncology
• Study coordinator: J. J. de Haan, MD, PhD
• Email: j.j.de.haan@umcg.nl
• Phone: +31 50 361 2821

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BEBT-209 plus chemotherapy in advanced/metastatic triple-negative breast cancer

  A new drug, BEBT-209, is being tested with standard chemotherapy to see if it helps people with locally advanced or metastatic triple-negative breast cancer.

  Recruiting at 2 sites Phase 2/3 BeBetter Med Inc · Guangzhou, Guangdong and 1 other locations · NCT07544056

• Naxitamab plus sacituzumab govitecan for metastatic triple-negative breast cancer

  This trial will test whether combining naxitamab with sacituzumab govitecan helps adults with metastatic triple-negative breast cancer.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07011654

• Sacituzumab govitecan with nivolumab, with or without relatlimab, for metastatic triple-negative breast cancer

  This trial tests whether adding nivolumab alone or nivolumab plus relatlimab to sacituzumab govitecan helps people with metastatic triple-negative breast cancer who have had one prior line of chemotherapy.

  Recruiting Phase 1/2 Yale University · New Haven, Connecticut · NCT06963905

• Evaluating Trop2-ADC treatment for advanced triple-negative breast cancer

  This study is testing a new treatment called Trop2-ADC, alone or with other therapies, to see if it helps people with advanced triple-negative breast cancer.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06851299

• Physical activity program to reduce cancer-related fatigue in men with metastatic testicular cancer

  This study is testing whether a physical activity program can help men with metastatic testicular cancer feel less tired and improve their overall quality of life.

  Recruiting at 3 sites Centre Leon Berard · Angers and 11 other locations · NCT05588700

• Combining SDX-7320 with Eribulin for Treating Breast Cancer

  This study is testing if adding the drug SDX-7320 to the standard chemotherapy eribulin can help people with metastatic triple-negative breast cancer and metabolic issues feel better.

  Recruiting at 10 sites Phase 2 Memorial Sloan Kettering Cancer Center · Miami, Florida and 9 other locations · NCT05570253

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.